The study reveals that resilience varies significantly by race, education, income, and insurance status, highlighting the ...

In the fourth part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line ...

In the fourth part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, outlines what he anticipates for the biosimilar adoption curve in ...

In the third part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

In the first part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data ...

In the third part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, recommends regulatory or verification mechanisms that can help safely ...

The industry veteran will lead the company’s next phase of growth, focusing on faster treatment initiation through integrated ...

In the second part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, explains how the private sector should strategically support and scale ...

Industry experts react to the developer’s role in preparing for value-based contracting, acknowledging that innovative agreements can support access when evidence is still maturing.

The intense demand for GLP-1 agonists stems from their proven efficacy in managing type 2 diabetes and, increasingly, in facilitating significant weight loss. However, patients often face substantial ...

In an interview with Pharmaceutical Executive, Corina Dutcus, SVP at Eisai, discussed nearly five-year follow-up data from the LEAP-002 study, which—despite missing its primary endpoint—reinforced ...